On Wednesday, April 10, the three manufacturers of insulin in the United States — Eli Lilly, Novo Nordisk and Sanofi — will testify before the House Energy and Commerce Oversight Subcommittee regarding their pricing practices. The three largest pharmacy benefit managers (PBMs) will also be appearing before the committee.
The hearing will be the second in two weeks regarding rising insulin prices and how the Congress can make the medicine more affordable. At the first hearing, “Priced Out of a Lifesaving Drug: The Human Impact of Rising Insulin Prices,” officers from the American Diabetes Association, JDRF and other prominent diabetes advocates testified before the committee.
According to a recent survey by the American Diabetes Association, “approximately 27 percent of the 535 patients surveyed indicated that cost has impacted their purchases or use of insulin.”
Want to learn how to save money on your insulin? Read “Insulin Prices: Four Ways to Pay Less.”